HILLEVAX INC. - COMMO

HilleVax Announces Executive Management Appointments and Promotions

09 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate

05 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

HilleVax to Participate in November Investor Conferences

10 Nov 2022 18:30:00 By Nasdaq GlobeNewswire

HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

10 Nov 2022 16:05:01 By Nasdaq GlobeNewswire

HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series

01 Sep 2022 17:18:14 By Nasdaq GlobeNewswire

HilleVax Announces Positive Recommendation from Safety Data Monitoring Committee for NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate

31 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

HilleVax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum

15 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

HilleVax Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

10 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate

20 Jul 2022 16:05:00 By Nasdaq GlobeNewswire

HilleVax Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

08 Jun 2022 16:01:00 By Nasdaq GlobeNewswire

HilleVax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

03 May 2022 16:00:00 By Nasdaq GlobeNewswire